ICTM logo
MRC CTU Trials at ASCO 2011

03 June 2011

Image of the American Society for Clinical Oncology logoThe American Society for Clinical Oncology (ASCO) Annual Meeting takes place from 3-7th June 2011 in Chicago. ASCO is the major international general cancer meeting, with expected attendance from over 30,000 people. Always known for high profile first presentations of new clinical trial results, this year features for the first time a "Clinical Trials Day" on Monday 6th June. The MRC CTU typically has several presentations at ASCO, and this year is no exception; the studies being presented are given below with links to their associated abstracts. We thank all the patients, clinicians and research staff who contributed to these studies.

Safety results from a randomised trial of perioperative epirubicin, cisplatin + capecitabine (ECX) +/- bevacizumab in patients with gastric or type II/II oesophagogastric junction adenocarcinoma.
A Okines, R. Langley, L. Thompson et al.
:: Sat 4th June, 8am—12pm. Gastrointestinal (Non-Colorectal) Cancer, general poster session, abs #4092. Hall A  

Evaluation of p53 mutation as a predictive biomarker for outcome to chemotherapy in ovarian cancer.
H Calvert, J Jackson, C Hutton et al.
:: Sat 4th June, 2pm—6pm. Tumour Biology, poster discussion session, abs #10522. Room S103

Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.
G Kristensen, T Perren, W Qian et al.
:: Sat 4th June, 4:00pm. Gynaecological Cancer, oral abstract session, abs #LBA5006. Room E354a

Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC).
G Chen, G Sonpavde, Claire Vale et al.
:: Sun 5th June, 8am—12pm. Genitourinary Cancer – general poster session, abs #4583. Hall A
A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN53643604).
RA Huddart, R Gabe, F Cafferty et al.
:: Mon 6th June, 9:30am. Genitourinary (Non-Prostate) oral abstract session, abs #4508. Hall D2
Developing a biomarker-stratified trial design in advanced colorectal cancer: the FOCUS-3 feasibility study.
T Maughan, RH Wilson, GT Williams et al.
:: Mon 6th June, 8am—12pm. Trials in Progress poster session, abs #TPS165. Hall A; board 44C
Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer.
S Michiels, A Mauguen, D Fisher et al.
:: Tues 7th June, 9:45am. Lung Cancer – Local-regional and Adjuvant Therapy Session/Small Cell, oral abstract session, abs #7004. Arie Crown Theatre